S-1/A: Abpro Holdings Faces Delisting Threat Amidst Deepening Losses and Going Concern Doubts

Abpro Holdings, a biotechnology company, has received multiple Nasdaq delisting notices and faces substantial doubt about its ability to continue as a going concern, reporting a net loss of $3.887 million in Q1 2025 and an accumulated deficit of $120 million.

Summary

• Abpro Holdings, Inc. (New Abpro) is a biotechnology company focused on developing next-generation antibody therapeutics for immuno-oncology and ophthalmology.
• The company reported a net loss of $3.887 million for the three months ended March 31, 2025, compared to a net income of $0.636 million for the same period in 2024 (which included a one-time $3.5 million reversal of a liability).
• As of March 31, 2025, Abpro had an accumulated deficit of $120.0 million and cash of $1.261 million.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year due to ongoing operating losses and a lack of financing commitments.
• The company received multiple delisting notices from Nasdaq in April 2025 for failing to meet the minimum $1.00 bid price, $15.0 million Market Value of Publicly Held Shares (MVPHS), and $50.0 million Market Value of Listed Securities (MVLS) requirements.
• Research and development expenses decreased by $0.7 million to $0.325 million in Q1 2025, primarily due to a majority of personnel being on furlough since October 2024 and a reduction in R&D activities while raising capital.
• General and administrative expenses increased by $0.8 million to $2.633 million in Q1 2025, mainly due to increased costs of operating as a public company (legal, accounting, insurance).
• The company has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (YA) to potentially sell up to $50.0 million in Common Stock, with 20,699,242 shares registered for resale by YA, representing 34.1% of total outstanding shares.
• Ian Chan was removed as Chief Executive Officer and Director for cause on March 3, 2025, and Miles Suk was appointed as the new CEO.
• Abpro is involved in several legal proceedings, including a lawsuit from a CRO vendor for approximately $0.7 million (judgment entered January 2024) and a dispute with Memorial Sloan Kettering Cancer Center (MSK) over $1.230 million in payments after a license agreement termination.
• The company is in breach of its license agreement with MedImmune/AstraZeneca due to missed development timelines for ABP-201, though management does not expect a material impact.
• Abpro has a pipeline of antibody product candidates, including ABP-102 (HER2/CD3 for HER2+ solid tumors) and ABP-201 (VEGF/ANG-2 for vascular eye diseases), with planned clinical trial initiations in 2026 and 2027 for various candidates.

Sentiment

Score: 2

Explanation: The company is in a highly precarious financial position, explicitly stating 'substantial doubt' about its ability to continue as a going concern. Multiple Nasdaq delisting notices, significant accumulated losses, and a very low cash balance underscore severe financial distress. While there are pipeline assets and partnerships, the immediate operational slowdown due to funding issues and ongoing legal disputes present major headwinds. The reliance on future capital raises, especially through potentially dilutive mechanisms like the SEPA, adds to the negative outlook.

Positives

• The company has proprietary antibody discovery (DiversImmune) and engineering (MultiMabTM) platforms, which management believes provide a competitive advantage.
• Abpro has established strategic partnerships with Celltrion (worldwide for ABP-102) and Abpro Bio (territorial for ABP-201), and NJCTTQ (territorial for ABP-150), which provide milestone payments and profit-sharing potential.
• ABP-102 and ABP-201 are expected to initiate clinical trials in 2026, indicating progress in the development pipeline.
• The company successfully raised $7.0 million in gross proceeds from a PIPE Financing concurrently with the Business Combination in November 2024.
• The company obtained stockholder approval on April 8, 2025, for the issuance of shares under the SEPA in excess of Nasdaq's 20% rule, enabling further capital raises through this mechanism.

Negatives

• The company has incurred significant recurring losses since inception, with an accumulated deficit of $120.0 million as of March 31, 2025.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year.
• The company received multiple Nasdaq delisting notices for failing to meet minimum bid price ($1.00), Market Value of Publicly Held Shares ($15.0 million), and Market Value of Listed Securities ($50.0 million) requirements.
• Research and development activities have decreased due to the need to raise additional capital, with a majority of R&D personnel on furlough since October 2024.
• The company is in breach of its license agreement with MedImmune/AstraZeneca due to missed IND and Phase II commencement target dates.
• A judgment of approximately $0.7 million was entered against the company in January 2024 in a lawsuit with a CRO vendor, with $0.806 million still outstanding as of March 31, 2025.
• The company's license agreement with Memorial Sloan Kettering Cancer Center (MSK) was terminated in September 2023 due to failure to make payments, with MSK demanding $1.230 million.
• The SARS-CoV-2 neutralizing antibody program, which advanced to a clinical trial, was unsuccessful.
• The company's cash position is very low at $1.261 million as of March 31, 2025, insufficient to meet anticipated cash needs for the next 12 months.
• The sale of a substantial percentage of outstanding Common Stock (34.1%) by Selling Securityholders under the SEPA, or the perception of such sales, could result in a significant decline in the public trading price of the Common Stock.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to ongoing operating losses and insufficient cash to fund operations for the next 12 months.
• Inability to raise additional capital on acceptable terms or at all, which could force delays, reductions, or termination of operations and drug development programs.
• High uncertainty and substantial risk inherent in drug development, with product candidates in early stages and never tested in human subjects.
• Potential for product candidates to fail in development or suffer extensive delays in preclinical studies and clinical trials.
• Market may not be receptive to product candidates based on novel therapeutic modalities, potentially leading to no revenue from sales or licensing.
• Breach of license agreements (e.g., MedImmune/AstraZeneca, MSK) could lead to loss of intellectual property rights or significant damages.
• Reliance on third-party collaborators (Celltrion, Abpro Bio, NJCTTQ) means limited control over their actions, potential for unsuccessful collaborations, or termination of agreements.
• Dependence on third-party manufacturing and supply partners for preclinical and clinical development materials, risking supply limitations, interruptions, or unsatisfactory quality.
• Intense competition from larger, better-funded biopharmaceutical companies and specialized biotechnology companies.
• Inability to attract and retain qualified key management, technical personnel, and employees, which would impair business plan implementation.
• Litigation and legal proceedings may substantially increase costs, divert management attention, and harm the business and reputation.
• Significant product liability risks inherent in the development, testing, manufacturing, and marketing of antibody treatments, with potential for insufficient insurance coverage.
• Misconduct by employees, principal investigators, consultants, and commercial partners could lead to enforcement actions, fines, and reputational harm.
• Failure or security breaches in internal computer systems or those of third-party contractors could disrupt product development programs and lead to data loss or liability.
• Non-compliance with environmental, health, and human safety laws and regulations could result in substantial costs, fines, or penalties.
• Adverse effects from natural disasters or man-made incidents on operations and third-party manufacturing facilities.
• Inability to obtain or protect intellectual property rights, or if rights are inadequate, leading to ineffective competition.
• Challenges to patent rights by other companies or organizations, potentially leading to costly litigation or invalidation of patents.
• Inadequate patent terms to protect competitive position for a sufficient amount of time.
• Changes in U.S. or foreign patent law or interpretation could diminish patent value.
• Third-party intellectual property rights could prevent commercialization or require costly licenses.
• Inability to protect the confidentiality of trade secrets, harming business and competitive position.
• Non-compliance with government patent agency requirements could lead to loss of patent rights.
• Inadequate protection of trademarks and trade names could hinder name recognition.
• Inability to obtain U.S. or foreign regulatory approval for product candidates, preventing commercialization.
• FDA or comparable foreign regulatory authorities may not accept data from clinical trials conducted outside the U.S.
• Ongoing regulatory obligations and continued regulatory review post-approval, potentially leading to significant additional expense, labeling restrictions, or market withdrawal.
• Healthcare legislative reform measures (e.g., ACA, IRA) may adversely affect business and results of operations through pricing regulations or reimbursement policies.
• Failure to comply with healthcare laws and regulations (e.g., Anti-Kickback Statute, False Claims Act) could result in enforcement actions and penalties.
• The Court of Chancery of the State of Delaware being the sole and exclusive forum for disputes could limit stockholders' ability to obtain a favorable judicial forum.
• Anti-takeover provisions in governing documents and Delaware law could make an acquisition more difficult and limit stockholder influence.
• Management's limited experience in managing a public company and increased expenses and administrative burdens as a public company.
• Material weaknesses identified in internal control over financial reporting could affect timely and reliable financial reports and weaken investor confidence.
• Restatement of prior period financial statements may affect investor confidence and raise reputational issues.
• Reduced SEC reporting requirements as an emerging growth company may make shares less attractive to investors.
• An active market for securities may not develop, affecting liquidity and price.
• The market price for Common Stock may decline due to various factors, including negative investor reactions or failure to meet analyst expectations.
• Future sales, or the perception of future sales, by current stockholders could cause the market price to decline significantly.
• No guarantee that warrants will ever be in the money; they may expire worthless or terms may be amended adversely.
• Uncertainty in predicting the actual number of shares to be sold under the SEPA or the gross proceeds, and potential lack of access to the full amount available.

Future Outlook

Abpro Holdings expects to continue incurring significant operating losses and negative cash flows for the foreseeable future as it advances its preclinical activities and clinical trials. The company plans to initiate Phase 1/2 clinical trials for ABP-102 in the first half of 2026 and Phase 1 clinical trials for ABP-201 in the second half of 2026. Clinical trials for ABP-110 and ABP-150 are expected to begin in the first half of 2027. The company intends to seek additional funding through equity and debt financings, collaboration agreements, and research grants to support its operations and drug development, acknowledging that obtaining such financing on acceptable terms is not assured.

Management Comments

• "Our management has concluded that uncertainties around our ability to raise additional capital raise substantial doubt about our ability to continue as a going concern, including drug development."
• "We believe that we are at a sufficiently mature development stage with both lead candidates that given adequate funding and, in the case of ABP-102, continued successful collaboration with Celltrion, these programs would be able to enter clinical trials in 2026."
• "We believe the likelihood that Warrant holders will exercise their Warrants, and therefore the amount of cash proceeds that we would receive is, among other things, dependent upon the market price of our Common Stock. If the market price for our Common Stock is less than the applicable exercise price of $3.83, subject to adjustment as described herein, we believe such holders will be unlikely to exercise their Warrants."
• "The overall decrease in expenses [R&D] was a result of the decrease in research and development activities while raising additional capital necessary to restart our research and development programs."
• "The Company does not believe this offering will have a significant impact on our ability to raise additional financing, although it may impact the per share price and shares issued in future capital raise."
• "We believe that our proprietary antibody platforms and approach overcome these limitations, however, we have yet to (i) produce antibodies on a scale needed for clinical trials or commercialization or (ii) evaluate any of our product candidates in a patient."
• "It is managements belief that ABP-102 has the potential to provide longer lasting or even curative results in a broader set of patients than are currently addressed by HER2-directed therapies."
• "We believe a more effective therapy [for DME and Wet AMD] that requires less frequent dosing would address the deficiencies of current therapy and be rapidly adopted as the new standard of care for the treatment of the disease."

Industry Context

Abpro Holdings operates in the highly competitive biotechnology and biopharmaceutical industries, specifically within the immuno-oncology and ophthalmology subsectors. The company is developing novel antibody constructs, including bispecific and multispecific antibodies, which represent a growing area in therapeutic development. Its focus on T-cell engagers for cancer and dual-targeting agents for ocular diseases aligns with industry trends seeking more effective and convenient treatments. However, the company faces significant competition from larger, well-funded multinational biopharmaceutical companies and specialized biotechnology firms that have more advanced clinical experience and resources. The market for HER2+ cancer therapies and ophthalmology treatments like Wet AMD and DME are substantial, but also feature established competitors and new entrants. Abpro's approach with its TetraBi antibody format aims to differentiate itself by potentially offering improved efficacy, safety, and dosing regimens compared to existing therapies and first/second-generation bispecific antibodies, as well as CAR T therapies.

Comparison to Industry Standards

• Abpro's ABP-102 is positioned as an improvement over currently approved HER2-targeting agents like Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), which are limited by efficacy in subsets of patients, side effects, and drug resistance. ABP-102 aims to provide more durable responses by redirecting cytotoxic T cells.
• ABP-201 is compared to current standard-of-care VEGF-targeted agents for DME and Wet AMD, such as Eylea (aflibercept), Lucentis (ranibizumab), and off-label Avastin (bevacizumab). Abpro believes ABP-201's dual inhibition of VEGF and ANG-2 and higher binding capacity will allow for less frequent dosing and overcome resistance mechanisms seen with VEGF-alone inhibitors, similar to the recently approved Vabysmo (faricimab).
• The company's TetraBi antibody format is presented as superior to first-generation Bispecific T-cell Engagers (BiTEs) due to longer half-life and potentially more convenient dosing, and superior to second-generation bispecific antibodies due to bivalent binding for tumor antigens and streamlined manufacturing (symmetrical structure).
• Abpro's TetraBi antibodies are presented as having several advantages over CAR T therapies, including simpler and more convenient administration (intravenous infusion in local clinics vs. complex multi-step process), no need for chemotherapy pre-treatment, easier toxicity management, and lower expected cost, despite CAR T therapies having demonstrated efficacy in liquid tumors.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit from a contract research organization (CRO) vendor resulted in a judgment of approximately $700,000 against the company in January 2024, with $806,000 still outstanding as of March 31, 2025.
• The license agreement with Memorial Sloan Kettering Cancer Center (MSK) was terminated in September 2023 due to the company's failure to make payments, with MSK demanding $1,230,000.
• The company is in breach of its license agreement with MedImmune/AstraZeneca due to missed IND and Phase II commencement target dates for ABP-201.
• A dispute exists with Mabwell (Shanghai) Bioscience Co., Ltd. regarding a claim for $3,300,000 under certain development milestones, which the company disputes.
• The company is engaged with the IRS regarding an excise tax liability of $4,401,000 assumed from ACAB, which the company believes is overstated.

Related Party Transactions

• The company has a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. (YA), a significant investor, for potential future equity sales up to $50.0 million.
• A Convertible Promissory Note for $3.0 million was entered into with YA in November 2024, with portions already converted into common stock.
• Abpro Bio International, Inc. (ABI), a significant investor (27.2% ownership), is a territorial partner for ABP-201 and made a $30.0 million equity investment in 2020.
• ABI also provided promissory notes to the company, with a $4.225 million balance converted into common stock as part of the PIPE Financing.
• Celltrion Inc., a strategic partner for ABP-102, provided an initial milestone payment of $2.0 million and a $2.0 million equity investment.
• Ian Chan, former CEO and director, received promissory notes for deferred bonuses ($176,625 principal) and was issued 850,000 warrants.
• Eugene Chan, a former director, received a promissory note for deferred bonuses ($123,638 principal) and had a consulting agreement that was terminated in 2024.
• An executive received a promissory note for up to $2.158 million in funding, with $1.997 million converted into 600,000 shares.
• A severance payment of $221,000 was made to an executive on November 21, 2024.
• A payment of $574,000 was made to Atlantic Coastal Acquisition Management II LLC (the Sponsor) in December 2024 in accordance with the Merger Agreement.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity issuances under the SEPA and warrant exercises. The ongoing operating losses, accumulated deficit, and 'going concern' doubt pose a substantial threat to investment value. Nasdaq delisting would severely impact liquidity and market price. Existing shareholders may experience a decline in value due to future sales by YA at lower prices.
• **Employees**: The company has furloughed nine employees and reduced R&D activities due to capital constraints, indicating job insecurity. The removal of the CEO for cause and the company's financial instability could impact employee morale and retention.
• **Customers/Partners**: Existing and future collaboration partners (Celltrion, Abpro Bio, NJCTTQ) face risks related to the company's financial viability and ability to meet its development obligations. Delays in clinical trials could impact the commercialization timelines of partnered product candidates.
• **Suppliers/Creditors**: The company has outstanding liabilities and legal disputes with vendors (e.g., CRO vendor, MSK, Mabwell), indicating potential payment issues and strained relationships. Creditors face uncertainty regarding repayment given the 'going concern' doubt.
• **Regulatory Authorities**: The company is subject to ongoing scrutiny from the SEC (filing compliance) and Nasdaq (listing requirements). Non-compliance with regulatory standards could lead to further penalties or restrictions.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement ($1.00 per share) by September 29, 2025.
• Regain compliance with Nasdaq's Market Value of Publicly Held Shares (MVPHS) requirement ($15.0 million) by October 7, 2025.
• Regain compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement ($50.0 million) by October 7, 2025.
• Initiate Phase 1/2 clinical trial for ABP-102 in the first half of 2026.
• Initiate Phase 1 clinical trial for ABP-201 in the second half of 2026.
• Initiate clinical trials for ABP-110 in the first half of 2027.
• Initiate clinical trials for ABP-150 in the first half of 2027.
• Continue to fundraise through equity and debt financings, collaboration agreements, and research grants.
• Address outstanding legal proceedings and disputed liabilities, including the CRO vendor lawsuit and claims from MSK and Mabwell.
• Implement and improve internal controls over financial reporting to address identified material weaknesses.

Key Dates

Recommendation

Keywords

Biotechnology, Antibody Therapeutics, Immuno-oncology, Ophthalmology, HER2+ Cancer, Wet AMD, Diabetic Macular Edema, Clinical Trials, Preclinical Development, SEC Filing, S-1/A, Nasdaq Delisting, Going Concern, Capital Raise, Standby Equity Purchase Agreement, SEPA, Dilution, Intellectual Property, Drug Development, Corporate Governance, Financial Reporting, Risk Factors, Abpro Holdings